Wall Street brokerages forecast that Clearside Biomedical Inc (NASDAQ:CLSD) will report ($0.36) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Clearside Biomedical’s earnings. The highest EPS estimate is ($0.24) and the lowest is ($0.56). Clearside Biomedical reported earnings of ($0.62) per share during the same quarter last year, which would indicate a positive year over year growth rate of 41.9%. The business is expected to announce its next quarterly earnings report on Wednesday, May 8th.

On average, analysts expect that Clearside Biomedical will report full-year earnings of ($1.35) per share for the current year, with EPS estimates ranging from ($1.83) to ($0.79). For the next financial year, analysts expect that the company will report earnings of ($0.89) per share, with EPS estimates ranging from ($1.21) to ($0.69). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD) last released its earnings results on Tuesday, March 12th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.13). The firm had revenue of $0.03 million during the quarter.

A number of equities research analysts recently commented on CLSD shares. Zacks Investment Research upgraded Clearside Biomedical from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a report on Thursday, January 3rd. Cowen reiterated a “hold” rating on shares of Clearside Biomedical in a report on Tuesday, January 22nd. Finally, ValuEngine downgraded Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Thursday, January 24th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. Clearside Biomedical presently has an average rating of “Hold” and a consensus price target of $10.32.

Hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in shares of Clearside Biomedical during the third quarter worth about $216,000. Virtu Financial LLC acquired a new position in Clearside Biomedical during the fourth quarter valued at approximately $57,000. Dimensional Fund Advisors LP acquired a new position in Clearside Biomedical during the third quarter valued at approximately $557,000. Fosun International Ltd acquired a new position in Clearside Biomedical during the fourth quarter valued at approximately $178,000. Finally, Alambic Investment Management L.P. acquired a new position in Clearside Biomedical during the fourth quarter valued at approximately $26,000. 35.49% of the stock is owned by institutional investors.

Shares of CLSD stock traded down $0.02 on Tuesday, reaching $1.24. 413,668 shares of the stock were exchanged, compared to its average volume of 626,976. The company has a debt-to-equity ratio of 0.40, a quick ratio of 4.10 and a current ratio of 4.10. Clearside Biomedical has a one year low of $0.99 and a one year high of $15.33.

About Clearside Biomedical

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.

See Also: What is a Leveraged Buyout (LBO)?

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.